AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential

Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.

Analyst Commentary

Recent Street research on Avantor has shifted toward a more cautious tone, with several high profile downgrades highlighting execution risks, reduced guidance, and limited visibility on a potential turnaround. Analysts point to weak or frustrating quarters, uncertainty around the timing of a recovery in key product areas, and management’s decision not to commit to earnings and sales growth next year while a review process is underway.

At the same time, there are still some constructive signals in the research flow, including raised price targets and continued positive ratings from certain firms that see value in the shares once execution stabilizes and the company’s review process produces more clarity.

Bullish Takeaways

• Bullish analysts have raised their price targets into the mid to high teens per share, with one move to US$16 and another to US$17. This indicates that some still see upside potential if Avantor can improve execution and restore confidence in its outlook.
• One firm increased its target to US$17 while maintaining an Outperform view after updating its model ahead of Q3 results. Under its assumptions, the current valuation leaves room for a better risk or reward profile once the earnings path becomes clearer.
• Another bullish analyst recently moved the target from US$14 to US$16 and kept an Outperform rating while adjusting longer term forecasts. This signals that, even with tempered growth and recovery assumptions, the shares can still screen as attractive on a P/E based framework.
• Across these positive notes, the common thread is a belief that, if Avantor can address operational headwinds and provide greater visibility on its medium term plan, current pricing may already reflect much of the execution concern. This could create potential for a re rating over time.

What's in the News

• Raymond James downgraded Avantor to Market Perform from Outperform, citing a "frustrating quarter," a sales miss, reduced guidance, execution risks, and lack of visibility on the outlook (Periodical).
• The law firm Kessler Topaz Meltzer & Check, LLP filed a securities fraud class action lawsuit against Avantor, alleging that investors were misled about competitive positioning and the impact of competition during the Class Period from March 5, 2024 to October 28, 2025 (Key Developments).
• Avantor issued full year 2025 guidance calling for organic revenue growth in a range of 3.5% to a 2.5% decline, signaling a cautious outlook for the year (Key Developments).
• The company announced a share repurchase program of up to US$500m, to be funded with cash and existing or other approved financing arrangements, with no stated expiration date (Key Developments).
• Avantor opened a new Centralized Service Center in Watertown, Massachusetts to provide off site lab services for Greater Boston and announced new bioprocessing products and collaborations, including a sterile sampling suite, PUPSIT assemblies, a "Smart Consumables" agreement with p-Chip, and a partnership with BlueWhale Bio focused on cell therapy manufacturing (Key Developments).

Valuation Changes

• The fair value estimate has edged up slightly, moving from about US$17.65 to around US$17.68 per share.
• The discount rate has risen, shifting from roughly 8.17% to about 8.85%, which implies a higher required return in the models.
• The revenue growth assumption has eased, moving from about 3.25% to roughly 2.25%.
• The net profit margin expectation has increased meaningfully, rising from around 7.24% to about 13.82%.
• The future P/E multiple assumption has been reduced, moving from roughly 28.82x to about 16.05x.